A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Paola Ghione; M. Lia Palomba; Markqayne D. Ray; Eve H. Limbrick-Oldfield; Jessica Owen; Steve Kanters; Sabela Bobillo; Maria Teresa Ribiero; Caron A. Jacobson; Sattva S. Neelapu; Herve Ghesquieres; Myrna Nahas; Sara Beygi; Anik R. Patel; John G. Gribben

doi:10.1016/j.clml.2024.01.011

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Paola Ghione, M. Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben

Lymphoma-Myeloma

Research output: Contribution to journal › Editorial › peer-review

Abstract

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.

Original language	English (US)
Journal	Clinical Lymphoma, Myeloma and Leukemia
DOIs	https://doi.org/10.1016/j.clml.2024.01.011
State	Accepted/In press - 2024

Keywords

Axi-cel
CAR T-cell
Efficacy
Indirect treatment comparison
Non-Hodgkin's lymphoma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2024.01.011

Cite this

Ghione, P., Palomba, M. L., Ray, M. D., Limbrick-Oldfield, E. H., Owen, J., Kanters, S., Bobillo, S., Ribiero, M. T., Jacobson, C. A., Neelapu, S. S., Ghesquieres, H., Nahas, M., Beygi, S., Patel, A. R., & Gribben, J. G. (Accepted/In press). A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.01.011

Ghione, P, Palomba, ML, Ray, MD, Limbrick-Oldfield, EH, Owen, J, Kanters, S, Bobillo, S, Ribiero, MT, Jacobson, CA, Neelapu, SS, Ghesquieres, H, Nahas, M, Beygi, S, Patel, AR & Gribben, JG 2024, 'A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.01.011

@article{bf460e34e51c4528aa42aa6b34d5fb8d,

title = "A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma",

abstract = "In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.",

keywords = "Axi-cel, CAR T-cell, Efficacy, Indirect treatment comparison, Non-Hodgkin's lymphoma",

author = "Paola Ghione and Palomba, {M. Lia} and Ray, {Markqayne D.} and Limbrick-Oldfield, {Eve H.} and Jessica Owen and Steve Kanters and Sabela Bobillo and Ribiero, {Maria Teresa} and Jacobson, {Caron A.} and Neelapu, {Sattva S.} and Herve Ghesquieres and Myrna Nahas and Sara Beygi and Patel, {Anik R.} and Gribben, {John G.}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

doi = "10.1016/j.clml.2024.01.011",

language = "English (US)",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

AU - Ghione, Paola

AU - Palomba, M. Lia

AU - Ray, Markqayne D.

AU - Limbrick-Oldfield, Eve H.

AU - Owen, Jessica

AU - Kanters, Steve

AU - Bobillo, Sabela

AU - Ribiero, Maria Teresa

AU - Jacobson, Caron A.

AU - Neelapu, Sattva S.

AU - Ghesquieres, Herve

AU - Nahas, Myrna

AU - Beygi, Sara

AU - Patel, Anik R.

AU - Gribben, John G.

PY - 2024

Y1 - 2024

N2 - In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.

AB - In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.

KW - Axi-cel

KW - CAR T-cell

KW - Efficacy

KW - Indirect treatment comparison

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85187506650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85187506650&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2024.01.011

DO - 10.1016/j.clml.2024.01.011

M3 - Editorial

C2 - 38365528

AN - SCOPUS:85187506650

SN - 2152-2650

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this